nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0343	0.0343	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0342	0.0342	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0338	0.0338	CbGpPWpGaD
Dicyclomine—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0292	0.0292	CbGpPWpGaD
Dicyclomine—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0291	0.0291	CbGpPWpGaD
Dicyclomine—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0289	0.0289	CbGpPWpGaD
Dicyclomine—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0284	0.0284	CbGpPWpGaD
Dicyclomine—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0283	0.0283	CbGpPWpGaD
Dicyclomine—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.028	0.028	CbGpPWpGaD
Dicyclomine—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0264	0.0264	CbGpPWpGaD
Dicyclomine—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0263	0.0263	CbGpPWpGaD
Dicyclomine—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0261	0.0261	CbGpPWpGaD
Dicyclomine—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0246	0.0246	CbGpPWpGaD
Dicyclomine—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0245	0.0245	CbGpPWpGaD
Dicyclomine—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0243	0.0243	CbGpPWpGaD
Dicyclomine—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0239	0.0239	CbGpPWpGaD
Dicyclomine—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0238	0.0238	CbGpPWpGaD
Dicyclomine—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0235	0.0235	CbGpPWpGaD
Dicyclomine—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0222	0.0222	CbGpPWpGaD
Dicyclomine—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0221	0.0221	CbGpPWpGaD
Dicyclomine—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0219	0.0219	CbGpPWpGaD
Dicyclomine—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0185	0.0185	CbGpPWpGaD
Dicyclomine—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0185	0.0185	CbGpPWpGaD
Dicyclomine—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0183	0.0183	CbGpPWpGaD
Dicyclomine—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0156	0.0156	CbGpPWpGaD
Dicyclomine—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0155	0.0155	CbGpPWpGaD
Dicyclomine—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0154	0.0154	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.0129	0.0129	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.0128	0.0128	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0126	0.0126	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0124	0.0124	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.0082	0.0082	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00812	0.00812	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00689	0.00689	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00669	0.00669	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00623	0.00623	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.006	0.006	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00582	0.00582	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00564	0.00564	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00562	0.00562	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00557	0.00557	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00548	0.00548	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00546	0.00546	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00543	0.00543	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00541	0.00541	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00527	0.00527	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0051	0.0051	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00508	0.00508	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00504	0.00504	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00483	0.00483	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00482	0.00482	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00477	0.00477	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00469	0.00469	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00468	0.00468	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00463	0.00463	CbGpPWpGaD
Dicyclomine—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00462	0.00462	CbGpPWpGaD
Dicyclomine—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00461	0.00461	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00437	0.00437	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00436	0.00436	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00431	0.00431	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00413	0.00413	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00412	0.00412	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00368	0.00368	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00367	0.00367	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00363	0.00363	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00357	0.00357	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00357	0.00357	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00356	0.00356	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00356	0.00356	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00353	0.00353	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00353	0.00353	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00352	0.00352	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00333	0.00333	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00332	0.00332	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00329	0.00329	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00306	0.00306	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00305	0.00305	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00302	0.00302	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.00279	0.00279	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00233	0.00233	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00232	0.00232	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0023	0.0023	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00208	0.00208	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00207	0.00207	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00205	0.00205	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00202	0.00202	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00201	0.00201	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00199	0.00199	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00189	0.00189	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00188	0.00188	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00188	0.00188	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00187	0.00187	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00186	0.00186	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00186	0.00186	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00183	0.00183	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00183	0.00183	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00181	0.00181	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00171	0.00171	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0017	0.0017	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00169	0.00169	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00132	0.00132	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00131	0.00131	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.0013	0.0013	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.0012	0.0012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00119	0.00119	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00118	0.00118	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00112	0.00112	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00111	0.00111	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.0011	0.0011	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00108	0.00108	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00108	0.00108	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00107	0.00107	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00101	0.00101	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00101	0.00101	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000996	0.000996	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000707	0.000707	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000704	0.000704	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000698	0.000698	CbGpPWpGaD
